Abstract
Background: Our purpose was to evaluate the predictive value of the lung immune prognostic index (LIPI) in patients with advanced non-small cell lung cancer (NSCLC) receiving different treatments. Methods: A systemic literature search of major databases of medicine was performed to explore the association of LIPI with different therapeutic effects in patients with advanced NSCLC, with overall survival (OS) as the surrogate marker. As such, HR and 95% CI were simultaneously selected to evaluate such an association. Results: A total of 4 studies involving 7,373 patients reported an association of the LIPI score with OS in advanced NSCLC patients. Further sorted by therapeutic regimen, the numbers of patients receiving immune checkpoint inhibitors (ICI), targeted therapy (TT), and chemotherapy (CT) were 3,651, 1,241, and 2,481, respectively. Overall, the good and intermediate LIPI groups (HR = 1.61; 95% CI 1.48–1.75; p < 0.01) showed no heterogeneity (I2 = 0%; p = 0.521), whereas the good and poor LIPI groups (HR = 2.74; 95% CI 2.26–3.33; p < 0.01) had a high heterogeneity (I2 = 67.9%; p = 0.019). For ICI, CT, and TT, the good and intermediate LIPI groups exhibited an HR of 1.70 (95% CI 1.49–1.93; p < 0.01) with I2 = 0% (p = 0.521), an HR 1.49 (95% CI 1.32–1.67; p < 0.01) with I2 = 0% (p = 0.437), and an HR of 1.85 (95% CI 1.45–2.36; p < 0.01) with I2 = 0% (p = 0.382), respectively. The good and poor LIPI groups had an HR of 3.46 (95% CI 2.72–4.39; p < 0.01) with I2 = 51.7% (p = 0.126), an HR of 2.22 (95% CI 1.85–2.66; p < 0.01) with I2 = 20.3% (p = 0.286), and an HR of 3.32 (95% CI 2.53–4.36; p < 0.01) with I2 = 0% (p = 0.703), for ICI, CT, and TT, respectively. Conclusions: In addition to being a possible prognostic indicator for advanced NSCLC patients receiving ICI, CT or TT, the LIPI may be used to stratify patients in randomized studies. These findings are of great help in deciding on the therapeutic strategy, and more well-designed studies are warranted to further verify them.
Journal Section:
Meta-Analysis
References
1.
Park
YJ
, Kuen
DS
, Chung
Y
. Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance
[J]
. Exp Mol Med
. 2018
Aug
;50
(8
):109
.
[PubMed]
1226-36132.
Peters
S
, Gettinger
S
, Johnson
ML
, Jänne
PA
, Garassino
MC
, Christoph
D
, et al. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)
[J]
. J Clin Oncol
. 2017
Aug
;35
(24
):2781
–9
.
[PubMed]
0732-183X3.
Spigel
DR
, Chaft
JE
, Gettinger
S
, Chao
BH
, Dirix
L
, Schmid
P
, et al. FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC
[J]
. J Thorac Oncol
. 2018
Nov
;13
(11
):1733
–42
.
[PubMed]
1556-08644.
Prelaj
A
, Tay
R
, Ferrara
R
, Chaput
N
, Besse
B
, Califano
R
. Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer
[J]
. Eur J Cancer
. 2019
Jan
;106
:144
–59
.
[PubMed]
0959-80495.
Mezquita
L
, Auclin
E
, Ferrara
R
, Charrier
M
, Remon
J
, Planchard
D
, et al. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer
[J]
. JAMA Oncol
. 2018
Mar
;4
(3
):351
–7
.
[PubMed]
2374-24376.
Tay
RY
, Chiramel
J
, Montague
E
, Wilson
F
, Summers
Y
, Blackhall
FH
, et al. Impact of blood-based biomarkers on survival outcomes with pembrolizumab in pre-treated advanced non-small cell lung cancer (NSCLC) patients (pts)
[J]
. Ann Oncol
. 2018
;29
:i529
. 0923-75347.
Kazandjian
D
, Gong
Y
, Keegan
P
, Pazdur
R
, Blumenthal
GM
. Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer
[J]
. JAMA Oncol
. 2019
Jul
;5
(10
):1481
–5
.
[PubMed]
2374-24378.
Sorich
MJ
, Rowland
A
, Karapetis
CS
, Hopkins
AM
. Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials
[J]
. J Thorac Oncol
. 2019
Aug
;14
(8
):1440
–6
.
[PubMed]
1556-08649.
Minami
S
, Ihara
S
, Komuta
K
. Pretreatment Lung Immune Prognostic Index Is a Prognostic Marker of Chemotherapy and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
[J]
. World J Oncol
. 2019
Feb
;10
(1
):35
–45
.
[PubMed]
1920-453110.
Blanc-Durand
F
, Auclin
E
, Planchard
D
, Aix
SP
, Hendriks
L
, Sullivan
IG
, et al. Association of lung immune prognostic index (LIPI) with survival of first line immune checkpoint inhibitors single agent or in combination with chemotherapy in untreated advanced NSCLC patients
[J]
. Ann Oncol
. 2019
;30
:i5
. 0923-753411.
Stang
A
. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
[J]
. Eur J Epidemiol
. 2010
Sep
;25
(9
):603
–5
.
[PubMed]
0393-299012.
Barili
F
, Parolari
A
, Kappetein
PA
, Freemantle
N
. Statistical Primer: heterogeneity, random- or fixed-effects model analyses?
[J]
. Interact Cardiovasc Thorac Surg
. 2018
Sep
;27
(3
):317
–21
.
[PubMed]
1569-929313.
Begg
CB
, Mazumdar
M
. Operating characteristics of a rank correlation test for publication bias
[J]
. Biometrics
. 1994
Dec
;50
(4
):1088
–101
.
[PubMed]
0006-341X14.
Egger
M
, Davey Smith
G
, Schneider
M
, Minder
C
. Bias in meta-analysis detected by a simple, graphical test
[J]
. BMJ
. 1997
Sep
;315
(7109
):629
–34
.
[PubMed]
0959-813815.
Mezquita
L
, Park
W
, Arbour
K
, Auclin
E
, Hendriks
L
, Planchard
D
, et al. Correlation of the Lung Immune Prognostic Index (LIPI) and PDL1 Status with Outcomes for Immune Checkpoint Inhibitors in Advanced NSCLC Patients
[J]
. J Thorac Oncol
. 2018
;13
(10
):S488
. 1556-086416.
Mezquita
L
, Auclin
E
, Charrier
M
, Ferrara
R
, Remon Masip
J
, Planchard
D
, et al. The Lung Immune Prognostic Index (LIPI), a predictive score for immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC) patients
[J]
. Ann Oncol
. 2017
;28
:v473
. 0923-753417.
Mielgo-Rubio
X
, Sereno
M M
, Sotelo-Lezama
M
, et al Validation of the Lung Immune Prognostic Index (LIPI): Useful to Identify Resistance to PD-1 Checkpoint Inhibitors in Pretreated Lung Cancer[J]. J Thorac Oncol, 2018,13(10):S488-S489. Barrón F, Mota B, Tirado L A R, et al. P2.24 Lung Immune Prognostic Index in Patients with Non-small Cell Lung Cancer Treated with Either Chemo or Immunotherapy
[J]
. J Thorac Oncol
. 2019
;14
(11
):S1195
.1556-086418.
Barrón F, Mota B, Tirado L A R, et al. P2.24 Lung Immune Prognostic Index in Patients with Non-small Cell Lung Cancer Treated with Either Chemo or Immunotherapy. J Thorac Oncol. 2019;14(11):S1195.
19.
Mielgo
RX
, Gomez
RA
, Antoñanzas
M
, et al. Applicability of lung immune prognostic index (LIPI) to predict efficacy of first-line pembrolizumab in advanced non-small cell lung cancer (NSCLC)
[J]
. Ann Oncol
. 2019
;30
:v619
–20
. 0923-753420.
Ruiz-Bañobre
J
, Areses-Manrique
MC
, Mosquera-Martínez
J
, Cortegoso
A
, Afonso-Afonso
FJ
, de Dios-Álvarez
N
, et al. Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy
[J]
. Transl Lung Cancer Res
. 2019
Dec
;8
(6
):1078
–85
.
[PubMed]
2218-675121.
Coussens
LM
, Werb
Z
. Inflammation and cancer
[J]
. Nature
. 2002
Dec
;420
(6917
):860
–7
.
[PubMed]
0028-083622.
Mantovani
A
, Allavena
P
, Sica
A
, Balkwill
F
. Cancer-related inflammation
[J]
. Nature
. 2008
Jul
;454
(7203
):436
–44
.
[PubMed]
0028-083623.
Hanahan
D
, Weinberg
RA
. Hallmarks of cancer: the next generation
[J]
. Cell
. 2011
Mar
;144
(5
):646
–74
.
[PubMed]
0092-867424.
Coffelt
SB
, Wellenstein
MD
, de Visser
KE
. Neutrophils in cancer: neutral no more
[J]
. Nat Rev Cancer
. 2016
Jul
;16
(7
):431
–46
.
[PubMed]
1474-175X25.
Drent
M
, Cobben
N A M
, Henderson
RF
, Wouters
EF
, van Dieijen-Visser
M
. Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation
[J]
. Eur Respir J
. 1996
Aug
;9
(8
):1736
–42
.
[PubMed]
0903-193626.
Gong
T
, Liu
J
, Jiang
J
, Zhai
YF
, Wu
CM
, Ma
C
, et al. The role of lactate deshydrogenase levels on non-small cell lung cancer prognosis: a meta-analysis
[J]
. Cell Mol Biol
. 2019
Jan
;65
(1
):89
–93
.
[PubMed]
0145-568027.
Yang
Y
, Xu
H
, Yang
G
, Yang
L
, Li
J
, Wang
Y
. The value of blood biomarkers of progression and prognosis in ALK-positive patients with non-small cell lung cancer treated with crizotinib
[J]
. Asia Pac J Clin Oncol
. 2020
Feb
;16
(1
):63
–9
.
[PubMed]
1743-755528.
Yu
SL
, Chen
HY
, Chang
GC
, Chen
CY
, Chen
HW
, Singh
S
, et al. MicroRNA signature predicts survival and relapse in lung cancer
[J]
. Cancer Cell
. 2008
Jan
;13
(1
):48
–57
.
[PubMed]
1535-610829.
Orlow
I
, Park
BJ
, Mujumdar
U
, Patel
H
, Siu-Lau
P
, Clas
BA
, et al. DNA damage and repair capacity in patients with lung cancer: prediction of multiple primary tumors
[J]
. J Clin Oncol
. 2008
Jul
;26
(21
):3560
–6
.
[PubMed]
0732-183X30.
Varga
A
, Bernard-Tessier
A
, Auclin
E
, Mezquita Pérez
L
, Baldini
C
, Planchard
D
, et al. Applicability of the lung immune prognostic index (LIPI) in patients with metastatic solid tumors when treated with immune checkpoint inhibitors (ICI) in early clinical trials
[J]
. Ann Oncol
. 2019
;30
:i2
. 0923-753431.
Meyers
DE
, Stukalin
I
, Vallerand
IA
, Lewinson
RT
, Suo
A
, Dean
M
, et al. The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors
[J]
. Cancers (Basel)
. 2019
Nov
;11
(11
):E1713
.
[PubMed]
2072-669432.
Sonehara
K
, Tateishi
K
, Komatsu
M
, et al Lung immune prognostic index as a prognostic factor in patients with small cell lung cancer[J]. Thorac Cancer, 2020. Belmaachi A, Auclin E, Vincent H, et al. ASSOCIATION OF LIPI SCORE WITH IMMUNOTHERAPY OUTCOMES IN ELDERLY POPULATION. [J]
. J Geriatr Oncol
. 2019
;10
(6
):S19
.1879-406833.
Belmaachi A, Auclin E, Vincent H, et al. Association of LIPI score with immunotherapy outcomes in elderly population. J Geriatr Oncol. 2019;10(6):S19.
34.
Benitez
JC
, Recondo
G
, Rassy
E
, Mezquita
L
. The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors
[J]
. Q J Nucl Med Mol Imaging
. 2020
Jun
;64
(2
):162
–74
.
[PubMed]
1824-478535.
Fougère
B
, Boulanger
E
, Nourhashémi
F
, Guyonnet
S
, Cesari
M
. Chronic Inflammation: Accelerator of Biological Aging
[J]
. J Gerontol A Biol Sci Med Sci
. 2017
Sep
;72
(9
):1218
–25
.
[PubMed]
1079-500636.
Yamada
Y
, Sakamoto
S
, Rii
J
, Yamamoto
S
, Kamada
S
, Imamura
Y
, et al. Prognostic value of an inflammatory index for patients with metastatic castration-resistant prostate cancer
[J]
. Prostate
. 2020
May
;80
(7
):559
–69
.
[PubMed]
0270-413737.
Dirican
A
, Kucukzeybek
BB
, Alacacioglu
A
, Kucukzeybek
Y
, Erten
C
, Varol
U
, et al. Do the derived neutrophil to lymphocyte ratio and the neutrophil to lymphocyte ratio predict prognosis in breast cancer?
[J]
. Int J Clin Oncol
. 2015
Feb
;20
(1
):70
–81
.
[PubMed]
1341-962538.
Berardi
R
, Rinaldi
S
, Santoni
M
, Newsom-Davis
T
, Tiberi
M
, Morgese
F
, et al. Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy
[J]
. Oncotarget
. 2016
May
;7
(18
):26916
–24
.
[PubMed]
1949-255339.
Liu
H
, Wu
Y
, Wang
Z
, Yao
Y
, Chen
F
, Zhang
H
, et al. Pretreatment platelet-to-lymphocyte ratio (PLR) as a predictor of response to first-line platinum-based chemotherapy and prognosis for patients with non-small cell lung cancer
[J]
. J Thorac Dis
. 2013
Dec
;5
(6
):783
–9
.
[PubMed]
2072-143940.
Espinosa
E
, Feliu
J
, Zamora
P
, González Barón
M
, Sánchez
JJ
, Ordón ez
A
, et al. Serum albumin and other prognostic factors related to response and survival in patients with advanced non-small cell lung cancer
[J]
. Lung Cancer
. 1995
Mar
;12
(1-2
):67
–76
.
[PubMed]
0169-5002© 2021 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2021
You do not currently have access to this content.
